Summary
45.35 2.26(5.24%)11/01/2024
Establishment Labs Holdings Inc (ESTA)
Establishment Labs Holdings Inc (ESTA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 5.03 | 1.41 | 11.66 | 7.11 | -10.45 | 43.74 | 133.04 | 83.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 45.35 | |
| Open | 43.36 | |
| High | 46.38 | |
| Low | 43.36 | |
| Volume | 301,689 | |
| Change | 2.17 | |
| Change % | 5.03 | |
| Avg Volume (20 Days) | 246,662 | |
| Volume/Avg Volume (20 Days) Ratio | 1.22 | |
| 52 Week Range | 17.00 - 60.12 | |
| Price vs 52 Week High | -24.57% | |
| Price vs 52 Week Low | 166.76% | |
| Range | 4.59 | |
| Gap Up/Down | -3.28 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,151 | |
| EBIDTA | -29,557,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 91.33 | |
| Book Value | 2.5660 | |
| Earnings Per Share | -1.3670 | |
| EPS Estimate Current Quarter | -0.3500 | |
| EPS Estimate Next Quarter | -0.2800 | |
| EPS Estimate Current Year | -1.4200 | |
| EPS Estimate Next Year | -0.9400 | |
| Diluted EPS (TTM) | -1.3670 | |
| Revenues | ||
| Profit Marging | -0.2755 | |
| Operating Marging (TTM) | -0.2011 | |
| Return on asset (TTM) | -0.0981 | |
| Return on equity (TTM) | -0.4607 | |
| Revenue TTM | 118,332,000 | |
| Revenue per share TTM | 4.9630 | |
| Quarterly Revenue Growth (YOY) | 0.2760 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 52,502,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 25.5985 | |
| Revenue Enterprise Value | 13.2252 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 24,003,700 | |
| Shares Float | 13,749,540 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.80 | |
| Institutions (%) | 65.42 | |
10/31 08:00 EST - businesswire.com
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects betwee.
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects betwee.
10/02 12:07 EST - gurufocus.com
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2
Shares of Establishment Labs Holdings Inc (ESTA, Financial) surged 9.25% in mid-day trading on Oct 2. The stock reached an intraday high of $44.42, before settling at $44.31, up from its previous close of $40.56.
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2
Shares of Establishment Labs Holdings Inc (ESTA, Financial) surged 9.25% in mid-day trading on Oct 2. The stock reached an intraday high of $44.42, before settling at $44.31, up from its previous close of $40.56.
09/26 17:02 EST - businesswire.com
Establishment Labs Receives U.S. FDA Approval for Motiva Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. “Today's approval is transformative for breast aesthetics in.
Establishment Labs Receives U.S. FDA Approval for Motiva Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. “Today's approval is transformative for breast aesthetics in.
08/06 18:16 EST - zacks.com
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
07/24 08:00 EST - businesswire.com
Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Can.
Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Can.
06/25 05:35 EST - zacks.com
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
05/23 08:00 EST - businesswire.com
Establishment Labs Announces Participation in Two Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 Jefferies Global Healthcare Conference being held June 5-6, 2024. Mr. Chacón.
Establishment Labs Announces Participation in Two Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 Jefferies Global Healthcare Conference being held June 5-6, 2024. Mr. Chacón.
05/08 18:11 EST - zacks.com
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.48 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.48 per share a year ago.
05/02 08:30 EST - businesswire.com
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re.
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re.
05/01 08:30 EST - businesswire.com
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants.
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants.
04/24 08:30 EST - businesswire.com
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Cana.
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Cana.
04/17 08:30 EST - businesswire.com
Establishment Labs Announces Participation in The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada. At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update on the clinical trial after comp.
Establishment Labs Announces Participation in The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada. At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update on the clinical trial after comp.
02/28 23:45 EST - seekingalpha.com
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
02/28 18:31 EST - zacks.com
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago.
02/22 08:00 EST - businesswire.com
Establishment Labs Announces Amended Credit Facility with Oaktree
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follow.
Establishment Labs Announces Amended Credit Facility with Oaktree
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follow.
02/21 11:06 EST - zacks.com
Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for
Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for
Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
01/22 08:00 EST - businesswire.com
Establishment Labs Announces Commercial Launch of Motiva Implants in China
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China. “China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer. “Establishment Labs was founded to make pr.
Establishment Labs Announces Commercial Launch of Motiva Implants in China
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China. “China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer. “Establishment Labs was founded to make pr.
01/09 08:06 EST - businesswire.com
Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a securities purchase agreement with select institutional accredited investors to purchase common shares of the Company, or pre-funded warrants in lieu thereof. The Company also announced preliminary unaudi.
Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a securities purchase agreement with select institutional accredited investors to purchase common shares of the Company, or pre-funded warrants in lieu thereof. The Company also announced preliminary unaudi.
01/02 08:00 EST - businesswire.com
Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mar.
Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mar.